Aptevo Therapeutics Inc. surges on market strength
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 23 2025
0mins
Should l Buy APVO?
Source: 8-K
Aptevo Therapeutics Inc. saw a significant price increase of 35.54%, reaching a 5-day high amid positive market conditions.
This surge is attributed to broad market strength, with the Nasdaq-100 up 0.23% and the S&P 500 up 0.17%. The stock's performance reflects a favorable environment for investors, suggesting a strong interest in biotech stocks.
The implications of this movement indicate a growing confidence in the sector, potentially driven by upcoming developments in drug trials and market dynamics.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy APVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on APVO
About APVO
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aptevo Therapeutics Announces Executive Changes
- CEO Retirement Announcement: Aptevo Therapeutics' CEO Marvin White will retire on April 1, 2026, transitioning to executive chair, which signifies a major leadership shift that could impact the company's strategic direction and investor confidence.
- New CEO Appointment: Chief Operating Officer Jeff Lamothe will be appointed as the new President and CEO, joining the board, and this appointment is expected to bring fresh management perspectives and operational efficiencies that could drive future growth.
- Board Structure Change: John E. Niederhuber will move from chairman to lead independent director, aiming to enhance corporate governance and improve the board's independence and decision-making capabilities, which may positively influence the company's long-term strategy.
- Reverse Stock Split: Aptevo Therapeutics announced a 1-for-18 reverse stock split, aimed at increasing the share price to improve market perception and attract more investor interest, potentially enhancing the company's financing capabilities.
See More
Aptevo (APVO) Implements 1-for-18 Reverse Stock Split, Reducing Shares to 1 Million
- Reverse Stock Split Plan: Aptevo Therapeutics is set to implement a 1-for-18 reverse stock split on December 29, 2025, reducing outstanding shares from approximately 18 million to about 1 million, aimed at increasing the share price to meet Nasdaq listing requirements.
- Market Reaction: Prior to the reverse split, APVO shares traded between $0.50 and $109.8 over the past year, closing at $0.60, down 34.73% from the previous day, indicating market concerns regarding the company's outlook.
- Historical Split Record: This marks Aptevo's second reverse stock split in 2025, following a 1-for-20 split that took effect on May 27, reflecting the company's ongoing efforts in stock price management.
- Shareholder Impact: The reverse split will automatically convert every 18 shares of common stock into 1 share, while the par value remains at $0.001, significantly reducing shareholders' equity and potentially affecting investor confidence and future fundraising capabilities.
See More
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split, Shares Plunge 38.4%
- Reverse Stock Split Announcement: Aptevo Therapeutics has announced a 1-for-18 reverse stock split effective December 29, converting every 18 shares into one, which has led to a significant 38.4% drop in share price to $0.57, indicating a negative market reaction despite prior shareholder approval in July.
- Severe Market Reaction: Following the reverse stock split announcement, Aptevo's shares plummeted sharply during Friday's session, reflecting investor concerns about the company's future prospects, which could adversely affect its financing capabilities and market confidence.
- Shareholder Approval Context: The final ratio for the reverse split was approved by the board in mid-December, despite having received shareholder support at the July annual meeting, yet the market's response raises questions about the company's governance and strategic direction.
- Industry Impact: The sharp decline in Aptevo's stock price may affect its competitive position in the biopharmaceutical sector, particularly regarding financing and partnership opportunities, as investors may reassess its investment value.
See More
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split, Shares Hit All-Time Low
- Reverse Stock Split Announcement: Aptevo Therapeutics has announced a 1-for-18 reverse stock split effective December 29, converting every 18 shares into one, aimed at boosting share price to meet listing requirements, yet this move has not prevented the stock from hitting an all-time low.
- Shareholder Approval: The reverse split was approved at the annual shareholder meeting in July, with the board confirming the final ratio in mid-December, demonstrating the company's commitment to structural adjustments with shareholder backing.
- Deteriorating Financial Performance: Aptevo recently reported a quarterly loss of $2.23 per share, exceeding analyst expectations of $2.09, with net losses increasing year-over-year from $5.1 million to $7.5 million, indicating heightened financial pressure on the company.
- Stock Price Decline: Following the announcement, Aptevo shares plummeted by 44.08%, trading at $0.5176, positioned at the lower end of its 52-week range, reflecting market pessimism regarding the company's future prospects.
See More
Biohaven Reports Phase 2 Study Failure for BHV-7000, Stock Drops
- Study Results Disappoint: Biohaven Ltd. (NYSE:BHVN) reported on Friday that its Phase 2 trial for BHV-7000 targeting major depressive disorder failed to meet its primary endpoint, resulting in a 10.4% drop in stock price, reflecting market concerns over the drug's development prospects.
- Market Volatility: On the same day, industrial stocks fell by 0.2%, indicating uncertainty in the economic outlook, which could impact investor confidence and future capital flows.
- Diverse Stock Performance: While Biohaven's stock declined, shares of Davis Commodities Ltd. (NASDAQ:DTCK) surged by 105.6% following the release of its financial results, highlighting a divergence in market reactions to different companies.
- Overall Market Dynamics: The Dow Jones index fell by 0.1%, while the NASDAQ and S&P 500 indices rose by 0.12% and 0.11%, respectively, suggesting a complex market sentiment as investors navigate between sectors.
See More
Gold Declines by More Than 1%; Darden Reports Disappointing Earnings
U.S. Stock Market Performance: U.S. stocks saw gains, with the Dow Jones up 0.37%, NASDAQ rising 1.07%, and S&P 500 increasing by 0.62%. Information technology shares led the rise, while materials stocks fell by 0.7%.
Darden Restaurants Financial Results: Darden Restaurants reported disappointing first-quarter earnings of $1.97 per share, missing the expected $2.00, and quarterly sales of $3.004 billion, below the $3.040 billion estimate.
Notable Stock Movements: 89bio, Inc. shares surged 86% after an acquisition announcement, while Intel Corporation's stock rose 27% following a partnership with NVIDIA. Conversely, Replimune Group, Inc. shares dropped 39% due to FDA feedback evaluation.
Economic Indicators: U.S. initial jobless claims fell to 231,000, lower than expected, and the Philadelphia Fed Manufacturing Index rose to +23.2, marking its highest level since January.
See More
Aptevo Therapeutics Announces Executive Changes
- CEO Retirement Announcement: Aptevo Therapeutics' CEO Marvin White will retire on April 1, 2026, transitioning to executive chair, which signifies a major leadership shift that could impact the company's strategic direction and investor confidence.
- New CEO Appointment: Chief Operating Officer Jeff Lamothe will be appointed as the new President and CEO, joining the board, and this appointment is expected to bring fresh management perspectives and operational efficiencies that could drive future growth.
- Board Structure Change: John E. Niederhuber will move from chairman to lead independent director, aiming to enhance corporate governance and improve the board's independence and decision-making capabilities, which may positively influence the company's long-term strategy.
- Reverse Stock Split: Aptevo Therapeutics announced a 1-for-18 reverse stock split, aimed at increasing the share price to improve market perception and attract more investor interest, potentially enhancing the company's financing capabilities.
See More
Aptevo (APVO) Implements 1-for-18 Reverse Stock Split, Reducing Shares to 1 Million
- Reverse Stock Split Plan: Aptevo Therapeutics is set to implement a 1-for-18 reverse stock split on December 29, 2025, reducing outstanding shares from approximately 18 million to about 1 million, aimed at increasing the share price to meet Nasdaq listing requirements.
- Market Reaction: Prior to the reverse split, APVO shares traded between $0.50 and $109.8 over the past year, closing at $0.60, down 34.73% from the previous day, indicating market concerns regarding the company's outlook.
- Historical Split Record: This marks Aptevo's second reverse stock split in 2025, following a 1-for-20 split that took effect on May 27, reflecting the company's ongoing efforts in stock price management.
- Shareholder Impact: The reverse split will automatically convert every 18 shares of common stock into 1 share, while the par value remains at $0.001, significantly reducing shareholders' equity and potentially affecting investor confidence and future fundraising capabilities.
See More
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split, Shares Plunge 38.4%
- Reverse Stock Split Announcement: Aptevo Therapeutics has announced a 1-for-18 reverse stock split effective December 29, converting every 18 shares into one, which has led to a significant 38.4% drop in share price to $0.57, indicating a negative market reaction despite prior shareholder approval in July.
- Severe Market Reaction: Following the reverse stock split announcement, Aptevo's shares plummeted sharply during Friday's session, reflecting investor concerns about the company's future prospects, which could adversely affect its financing capabilities and market confidence.
- Shareholder Approval Context: The final ratio for the reverse split was approved by the board in mid-December, despite having received shareholder support at the July annual meeting, yet the market's response raises questions about the company's governance and strategic direction.
- Industry Impact: The sharp decline in Aptevo's stock price may affect its competitive position in the biopharmaceutical sector, particularly regarding financing and partnership opportunities, as investors may reassess its investment value.
See More
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split, Shares Hit All-Time Low
- Reverse Stock Split Announcement: Aptevo Therapeutics has announced a 1-for-18 reverse stock split effective December 29, converting every 18 shares into one, aimed at boosting share price to meet listing requirements, yet this move has not prevented the stock from hitting an all-time low.
- Shareholder Approval: The reverse split was approved at the annual shareholder meeting in July, with the board confirming the final ratio in mid-December, demonstrating the company's commitment to structural adjustments with shareholder backing.
- Deteriorating Financial Performance: Aptevo recently reported a quarterly loss of $2.23 per share, exceeding analyst expectations of $2.09, with net losses increasing year-over-year from $5.1 million to $7.5 million, indicating heightened financial pressure on the company.
- Stock Price Decline: Following the announcement, Aptevo shares plummeted by 44.08%, trading at $0.5176, positioned at the lower end of its 52-week range, reflecting market pessimism regarding the company's future prospects.
See More
Biohaven Reports Phase 2 Study Failure for BHV-7000, Stock Drops
- Study Results Disappoint: Biohaven Ltd. (NYSE:BHVN) reported on Friday that its Phase 2 trial for BHV-7000 targeting major depressive disorder failed to meet its primary endpoint, resulting in a 10.4% drop in stock price, reflecting market concerns over the drug's development prospects.
- Market Volatility: On the same day, industrial stocks fell by 0.2%, indicating uncertainty in the economic outlook, which could impact investor confidence and future capital flows.
- Diverse Stock Performance: While Biohaven's stock declined, shares of Davis Commodities Ltd. (NASDAQ:DTCK) surged by 105.6% following the release of its financial results, highlighting a divergence in market reactions to different companies.
- Overall Market Dynamics: The Dow Jones index fell by 0.1%, while the NASDAQ and S&P 500 indices rose by 0.12% and 0.11%, respectively, suggesting a complex market sentiment as investors navigate between sectors.
See More
Gold Declines by More Than 1%; Darden Reports Disappointing Earnings
U.S. Stock Market Performance: U.S. stocks saw gains, with the Dow Jones up 0.37%, NASDAQ rising 1.07%, and S&P 500 increasing by 0.62%. Information technology shares led the rise, while materials stocks fell by 0.7%.
Darden Restaurants Financial Results: Darden Restaurants reported disappointing first-quarter earnings of $1.97 per share, missing the expected $2.00, and quarterly sales of $3.004 billion, below the $3.040 billion estimate.
Notable Stock Movements: 89bio, Inc. shares surged 86% after an acquisition announcement, while Intel Corporation's stock rose 27% following a partnership with NVIDIA. Conversely, Replimune Group, Inc. shares dropped 39% due to FDA feedback evaluation.
Economic Indicators: U.S. initial jobless claims fell to 231,000, lower than expected, and the Philadelphia Fed Manufacturing Index rose to +23.2, marking its highest level since January.
See More
